A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) vs standard of care
Thomas Hutson, Memorial Sloan Kettering Cancer Center, New York, NY presents A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRC...
Author: kidneycancer
Added: 11/07/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology